CHK1抑制在软组织肉瘤中的生物学与临床意义
该研究通过10株软组织肉瘤(STS)细胞系体外筛选、TP53突变型与野生型患者来源异种移植模型及I期临床试验,评估CHK1抑制剂GDC-0575联合化疗的活性。结果显示GDC-0575可废除DNA损伤诱导的S期和G2-M期检查点、加重DNA双链断裂并诱导凋亡,与吉西他滨在TP53功能完好模型中呈协同或相加效应;I期研究中2例转移性TP53突变型STS患者获持久缓解。
要点
- GDC-0575可废除STS细胞DNA损伤诱导的S和G2-M检查点并诱导凋亡。
- GDC-0575联合吉西他滨在TP53功能完好而非缺陷的肉瘤模型中呈协同或相加效应。
- I期研究中2例TP53突变型STS患者联合低剂量吉西他滨获持久缓解,支持进一步II期研究。
核心结论
- GDC-0575联合化疗在TP53缺陷型STS中显示协同作用,I期临床观察到TP53突变型患者的持久缓解,值得进一步II期研究。
研究设计与样本
- 体外系统筛选10株STS细胞系,评估GDC-0575联合化疗对增殖、死亡和细胞周期的影响。
- 体内采用TP53突变型和TP53野生型STS患者来源异种移植模型进行实验。
- I期研究评估GDC-0575联合吉西他滨在TP53突变型和野生型STS患者中的临床活性。
主要发现
- GDC-0575废除DNA损伤诱导的S和G2-M检查点,加重DNA双链断裂并诱导STS细胞凋亡。
- GDC-0575与吉西他滨在体外和体内TP53功能完好模型中呈协同或相加效应,TP53缺陷模型未见此效应。
- I期研究中2例转移性TP53突变型STS患者接受极低剂量吉西他滨仍获持久缓解,1例TP53野生型患者无临床获益。
- 1例用药1年后出现继发耐药的患者基因分析显示DNA2螺旋结构域一个原有功能缺失突变丢失。
临床怎么用
- 提示CHK1抑制剂联合化疗可能作为TP53缺陷型STS的潜在治疗策略,需进一步II期验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibition of ChK1 appears as a promising strategy for selectively potentiate the efficacy of chemotherapeutic agents in G1 checkpoint-defective tumor cells such as those that lack functional p53 protein. The p53 pathway is commonly dysregulated in soft-tissue sarcomas (STS) through mutations affecting TP53 or MDM2 amplification. GDC-0575 is a selective ATP-competitive inhibitor of CHK1. METHODS: We have performed a systematic screening of a panel of 10 STS cell lines by combining the treatment of GDC-0575 with chemotherapy. Cell proliferation, cell death and cell cycle analysis were evaluated with high throughput assay. In vivo experiments were carried out by using TP53-mutated and TP53 wild-type patient-derived xenograft models of STS. Clinical activity of GDC-0575 combined with chemotherapy in patients with TP53-mutated and TP53 wild-type STS was also assessed. RESULTS: We found that GDC-0575 abrogated DNA damage-induced S and G2-M checkpoints, exacerbated DNA double-strand breaks and induced apoptosis in STS cells. Moreover, we observed a synergistic or additive effect of GDC-0575 together with gemcitabine in vitro and in vivo in TP53-proficient but not TP53-deficient sarcoma models. In a phase I study of GDC-0575 in combination with gemcitabine, two patients with metastatic TP53-mutated STS had an exceptional, long-lasting response despite administration of a very low dose of gemcitabine whereas one patient with wild-type TP53 STS had no clinical benefit. Genetic profiling of samples from a patient displaying secondary resistance after 1 year showed loss of one preexisting loss-of-function mutation in the helical domain of DNA2. CONCLUSION: We provide the first preclinical and clinical evidence that potentiation of chemotherapy activity with a CHK1 inhibitor is a promising strategy in TP53-deficient STS and deserves further investigation in the phase II setting.
引用
- Laroche-Clary A, Lucchesi C, Rey C, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018. PMID: 29409053. doi:10.1093/annonc/mdy039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。